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Biologics drug substance is ideally stored and transported in a frozen state to minimize potential temperature 
related instabilities. Currently, BMS utilizes compressor-based freezers or liquid N2 (LN2) blast freezer units that 
achieve cooling by convection. These processes are relatively long (up to 3 days), and provide limited capacity 
(e.g., up to 8 containers per blast-freezer unit). 
 
With the projected improvements in Drug Substance (DS) process yields (for example, a product reaching up to 
80 filled containers per batch), the existing blast freezers capacity could easily exceed full utilization.  This level 
of throughput would lead to the freezing process unit operation becoming a cadence limiting step and resulting 
in increased hold times prior to freezing. This poster describes successful first time implementation of active 
plate HOF freezing and thawing technology for freezing and thawing a biologics bulk drug substance at DS and 
Drug Product (DP) manufacturing sites (Figure 1). The poster will describe various challenges identified and 
resolved before technology implementation in manufacturing. The HOF technology led to faster (up to 2 cycles 
per day, 10 containers per cycle per unit) and a more robust freezing process (consistent freezing of a wide 
variety of loads). Furthermore, the HOF technology has application for thawing DS at the DP sites. In this 
poster, we will also present our roll out plans for implementation of the active-plate as the platform BMS 
technology for freezing and thawing DS, across both internal network and external partners.  
 
The lessons learned during first implementation are being leveraged across the network. The work outlined in 
this poster is highly relevant to the central theme of 2019 meeting (The Next Generation of Biochemical and 
Molecular Engineering: The role of “emerging technologies” in tomorrow’s products and processes) since the 
plate-based freeze-thaw technology eliminates freezing and thawing processes becoming cadence limiting 
steps at a time of increasing recombinant protein throughputs. 
 
 
Figure 1 – Improvements in freeze and thaw process durations for 12L Flexible Freeze Thaw Plate (FFTp) 
containers using HOF technology: (A) Comparison of HOF freezing durations with liquid N2 blast freezing duration; 
(B) Comparison of HOF thaw duration with room temperature thaw duration 
